Bristol Myers Squibb sets same price for schizophrenia drug in UK and US
PositiveFinancial Markets

Bristol Myers Squibb has announced that it will set the same price for its new schizophrenia drug in both the UK and the US, a move that is being praised for promoting fairness in drug pricing. This decision is significant as it reflects a growing trend towards transparency and equity in the pharmaceutical industry, potentially benefiting patients in both countries who rely on this medication for their mental health.
— Curated by the World Pulse Now AI Editorial System